|
Patient characteristics
|
Intensified myeloablative conditioning (n = 81)
|
Standard myeloablative conditioning (n = 104)
|
P-value
|
|---|
|
Female/Male
|
31(38.3%)/50(61.7%)
|
41(39.4%)/63(60.6%)
|
NS
|
|
Median age, years (range)
|
26(14–54)
|
28(12–63)
|
NS
|
|
Disease
| | | |
|
ALL
|
42 (51.85%)
|
23 (22.1%)
|
P<0.001
|
|
AML
|
17 (21.0%)
|
43(41.4%)
| |
|
ALAL
|
12 (14.8%)
|
12 (11.5%)
| |
|
CML
|
6 (7.4%)
|
22 (21.2%)
| |
|
HD/NHL
|
3(3.7%)
|
2 (1.9%)
| |
|
MDS
|
0 (0%)
|
2 (1.9%)
| |
|
BPDCN
|
1 (1.25%)
|
0 (0%)
| |
|
Disease status at the time of transplants
| | | |
|
CR (including CML-CP)
|
31 (38.3%)
|
94 (90.4%)
|
P<0.001
|
|
NR (including CML-AP and BC)
|
50 (61.7%)
|
10 (9.6%)
| |
|
EBV serostatus
| | | |
|
D-/R-
|
15(18.5 %)
|
21(20.2 %)
|
NS
|
|
D+/R-
|
23(28.4%)
|
27(26.0%)
| |
|
D-/R+
|
16(19.8%)
|
22(21.1%)
| |
|
D+/R+
|
27(33.3%)
|
34(32.7%)
| |
|
CMV serostatus
| | | |
|
D-/R-
|
4(4.9%)
|
5(4.8%)
|
NS
|
|
D+/R-
|
3(3.7%)
|
4(3.85%)
| |
|
D-/R+
|
3(3.7%)
|
2(1.95%)
| |
|
D+/R+
|
71(87.7%)
|
93(89.4%)
| |
|
Donor type
| | | |
|
Sibling donor
|
44(54.3%)
|
73 (70.2%)
|
P = 0.010
|
|
Family donor
|
11 (13.6%)
|
3 (2.9%)
| |
|
Unrelated donor
|
26(32.1%)
|
28 (26.9%)
| |
|
HLA typing
| | | |
|
HLA-identical
|
49 (60.5%)
|
79 (76.0%)
|
NS
|
|
One allele mismatched
|
15 (18.5%)
|
15 (14.4%)
| |
|
Two alleles mismatched
|
8 (9.9%)
|
8 (7.7%)
| |
|
Three alleles mismatched
|
1 (1.2%)
|
1 (0.95%)
| |
|
Four alleles mismatched
|
6 (7.4%)
|
1 (0.95%)
| |
|
Five alleles mismatched
|
2 (2.5%)
|
0 (0.0%)
| |
|
Stem cell source
| | | |
|
PBSCs
|
63 (77.8%)
|
90 (86.5%)
|
NS
|
|
BM
|
1 (1.2%)
|
0 (0.0%)
| |
|
PBSCs + BM
|
17(21.0%)
|
14 (13.5%)
| |
|
Median CD34+ cells per graft, ×106/kg (range)
|
8.8(5.4-11.9)
|
8.1(5.2-11.7)
|
NS
|
|
Conditioning
| | | |
|
TBI + CY
| |
36 (34.6%)
|
NA
|
|
Bu + CY
| |
40 (38.5%)
| |
|
Bu + Flu
| |
28(26.9%)
| |
|
Flu + Ara-c + TBI + CY
|
49 (60.5%)
| | |
|
TBI + CY + VP-16
|
32 (39.5%)
| | |
|
GVHD prophylaxis
| | | |
|
CsA
|
4 (5.0%)
|
2 (1.9%)
|
NS
|
|
CsA + MTX
|
33 (40.75%)
|
62 (59.6%)
| |
|
CsA + MTX + ATG
|
28 (34. 5%)
|
27 (26.0%)
| |
|
CsA + MTX + MMF
|
3 (3.7%)
|
2 (1.9%)
| |
|
CsA + MTX + ATG + MMF
|
13 (16.05%)
|
11 (10.6%)
| |
- ALL = acute lymphoblastic leukemia; AML = acute myelogenous leukemia; ALAL = acute leukemia of ambiguous lineage; CML = chronic myelogenous leukemia; HD = Hodgkin’s disease; NHL = Non-Hodgkin’s lymphoma; MDS = myelodysplastic syndromes; BPDCN = blastic plasmacytoid dendritic cell neoplasm;CR = complete remission; CP = chronic phase; NR = not in CR; AP = accelerated phase; BC = blastic crisis; D = donor; R = recipient; PBSCs = peripheral blood stem cells; BM = bone marrow; TBI = total body irradiation; CY = cyclophosphamide; BU = busulfan; FLU = fludarabine; Ara-c = cytarabine; VP16 = etoposide; GVHD = graft-versus-host disease; CSA = cyclosporine A; MTX = methotrexate; ATG = antithymocyte globulin; MMF = mycophenolate mofetil; NS = not significant; NA = not applicable.
